Intratumoral injection of anti-CTLA-4 and OX40 agonists depleted tumor-infiltrating Tregs in murine lymphoma models.407 A phase 1 clinical study (NCT03636503) of PF-04518600 (the OX40 agonist) in combination with utomilumab (4-1BB agonist) and rituximab or in combination with avelumab (anti-PD-L1) and rituximab is ongoing in aggressive B-NHLs. Here, TNFRSF4 is linked to lymphoma.